Endocrine Abstracts

Introduction: The variable tumor behavior in patients with gastro-entero-pancreatic neuroendocrine tumors (GEPNETs) is challenging. Current general biomarkers are insufficient to predict the disease course. An emerging biomarker is the NETest, a blood-based gene signature that can predict disease status based on the expression of genes involved in tumor biology. While promising, the accuracy and reproducibility of results in daily practice during years of follow up has never b...

Abstract: Transarterial embolisation (TAE) is an effective treatment for liver metastases from neuroendocrine tumour (NET). It reduces arterial blood flow to the tumour resulting in ischemia and necrosis. In this single centre retrospective study the effectiveness and safety of TAE was evaluated.Patients and methods: 30 patients with histological confirmed gastro-entero-pancreatic NET with liver metastases were investigated. Tumour response, decline in s...

Background: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are commonly characterized by high-density expression of somatostatin receptors (SSTRs), which can be targeted by radiopharmaceutical therapy (RPT) via radiolabeled somatostatin analogues (SSAs). RYZ101 (225Ac-DOTATATE) is a first-in-class, highly potent alpha-emitting RPT being developed for the treatment of SSTR+ solid tumors. Alpha-particles (such as those emitted by 225<...

Background: There is currently no effective blood biomarker for lung neuroendocrine neoplasia diagnosis and management. We describe the clinical utility of a 51 neuroendocrine-specific gene expression set in blood to diagnose bronchopulmonary neuroendocrine tumors (BPNETs) and define their clinical status.Methods: The discovery set included BPNETs (n=154) and controls (n=90), randomly assigned (1:1) to a test and validation set. Specifi...